Capped pyrazinoylguanidine sodium channel blockers
US8507497B2 · kind B2 · utility
25Cited by
42References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 9, 2012 |
| Grant date | Aug 13, 2013 |
| Priority date | — |
| Expiry date | May 9, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a method of treating cystic fibrosis in which an effective amount of a compound represented by formula (I) is administered to a subject in need thereof:where the structural variables are as defined herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.